ABSTRACT
Longitudinal studies of plasma anti-V2 Abs. To determine whether the deficiency of 149 V2 Abs is temporary or stable, we analyzed plasma samples from six V2 Ab-deficient donors 150 over 11-54 months of observation and plasma samples from six V2 Ab-reactive donors over 28-151 60 months of observation (Table 1) . These sequential samples were titrated and screened against 152 five Env antigens: V1V2 A244 -gp70, cyclic V3 A244 peptide, gp120 A244 , gp41 MN , and p24 HXB2 (Fig. 153 3). Titers of anti-V2 A244 Abs in the V2-deficient group were undetectable (<1:100 dilution) (Fig. 154 3A) and designated as a 50% binding titer of 10 0 (Fig. 4) have some influence on the immunogenicity of V2. From each plasma virus, 3 to 9 gp120 179 sequences were produced and used to generate consensus sequences for all 12 subjects (Table   180 2S). We analyzed the amino acid (AA) length, number of putative N-linked glycosylation sites,
181
isoelectric point (pI), and charge of the V2 and V1 regions. For each region, we compared these 182 features in the V2-deficient vs V2-reactive groups (Table 2, Table S3 ). In the V2 region, AA (Table 3) .
188
We also analyzed the β-sheet propensity for the central conserved segment (E153 to 189 I184) and the α-helix propensity (K168 to V172) of the V2 region. The β-sheet propensity
190
correlates with neutralization sensitivity of the virus (13) and may suggest a different 191 immunogenicity profile, i.e., preferential presentation of different epitopes. The α-helix
192
propensity is an estimate of the helical conformation, which is recognized by anti-V2 peptide 193 mAbs such as CH58 (14) and putatively induces anti-V2p Abs; lower propensity suggest a higher tendency to form a helical structure. The two parameters were comparable between the 195 V2-deficient and V2-reactive groups (Table 3, Table S3 measured by OD were not unusually high (9).
227
In the present study, the frequency of plasma anti-V2 Abs was between 53% and 85% for 228 the three V1V2 fusion proteins and was comparable to results in the RV144 study, which 229 reported 84% frequency, possibly due to using the same V1V2 fusion proteins for screening (9).
230
In previous studies of sera of individuals chronically infected with HIV-1, anti-V2 Abs were 231 detected at a much lower frequency (from 12% to 48%), but either the V2 antigens tested were 232 different or plasma Abs were analyzed by different methods (4-7).
233
The level of anti-V2 Abs showed broad variations, in contrast to a relatively high level of
234
Abs against V3, gp120, and gp41, as measured by OD and also by 50% titers (Fig. 1 ). Eight out 235 of 79 (10%) plasma samples had no reactivity to any of the six V2 antigens in longitudinal 236 studies over 8 to 54 months, while all plasma samples reacted to gp120 and gp41 (Fig. 2C) .
237
There was a strong correlation between ODs of plasma Abs binding to V2 antigens and to 238 gp120/gp41 (Fig. 5 ). For example, plasma samples with high or low OD for gp120 and gp41 Abs also had high or low levels of anti-V2 Abs, respectively, suggesting that a patient's capacity to 240 mount Ab responses to HIV-1, in general, is associated with the level of anti-V2 Abs.
241
We hypothesized that, in addition to a low Ab response to Env proteins, the lack of anti- 
249
Given that additional glycosylation sites in the V2 region confer resistance to neutralization by 250 V2 mAbs, this may also have an impact on immunogenicity, resulting in weaker or lack of Ab 251 response, particularly in subjects with poor humoral immune response to infecting virus.
252
The charge and pI of the V2 region were also lower in the V2-deficient versus V2-253 reactive panel of sequences ( plate at 1 µg/mL; plasma were diluted by 10-fold dilutions starting from 1:100 to 1:1,000,000. from virus of donor's plasma: MDC230-1 and MDC200-2 (this allows testing of two plasma Abs vs. autologous antigens). Plasma samples were screened by standard ELISA at 1:100 dilution against antigens coated at 1 µg/mL; biotinylated cyclic V2 and V3
peptides were immobilized at 1 µg/mL on the streptavidin coated plates. The values bold are above cutoff (mean OD of 6 control healthy plasma samples + 3 standard deviation). 
